Roche wins FDA nod for new Vabysmo format (OTCQX:RHHBF)
2024-07-05
Waldemarus Roche (OTCQX:RHHBY) unit Genentech announced Friday that the U.S. Food and Drug Administration (FDA) approved a new ready-to-use format for its eye disease therapy Vabysmo to treat three leading causes of vision loss. Accordingly, the bispecific antibody, also known as faricimab, will be available in a new format forContinue Reading